• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝类器官研究的十年进展:疾病建模的新突破

A decade of liver organoids: Advances in disease modeling.

机构信息

Guangzhou Laboratory, No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island, Guangzhou, Guangdong, China.

Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China.

出版信息

Clin Mol Hepatol. 2023 Jul;29(3):643-669. doi: 10.3350/cmh.2022.0428. Epub 2023 Mar 6.

DOI:10.3350/cmh.2022.0428
PMID:36880210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10366802/
Abstract

Liver organoids are three-dimensional cellular tissue models in which cells interact to form unique structures in culture. During the past 10 years, liver organoids with various cellular compositions, structural features, and functional properties have been described. Methods to create these advanced human cell models range from simple tissue culture techniques to complex bioengineering approaches. Liver organoid culture platforms have been used in various research fields, from modeling liver diseases to regenerative therapy. This review discusses how liver organoids are used to model disease, including hereditary liver diseases, primary liver cancer, viral hepatitis, and nonalcoholic fatty liver disease. Specifically, we focus on studies that used either of two widely adopted approaches: differentiation from pluripotent stem cells or epithelial organoids cultured from patient tissues. These approaches have enabled the generation of advanced human liver models and, more importantly, the establishment of patient-tailored models for evaluating disease phenotypes and therapeutic responses at the individual level.

摘要

肝类器官是一种三维细胞组织模型,其中细胞相互作用,在培养中形成独特的结构。在过去的 10 年中,已经描述了具有各种细胞组成、结构特征和功能特性的肝类器官。创建这些先进的人类细胞模型的方法从简单的组织培养技术到复杂的生物工程方法不等。肝类器官培养平台已被用于各种研究领域,从模拟肝脏疾病到再生治疗。本综述讨论了肝类器官如何用于模拟疾病,包括遗传性肝脏疾病、原发性肝癌、病毒性肝炎和非酒精性脂肪性肝病。具体来说,我们专注于使用两种广泛采用的方法之一的研究:多能干细胞的分化或从患者组织培养的上皮类器官。这些方法使先进的人类肝脏模型的产生成为可能,更重要的是,为在个体水平上评估疾病表型和治疗反应建立了基于患者的模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc9/10366802/f983a874da6a/cmh-2022-0428f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc9/10366802/9149859cd8a4/cmh-2022-0428f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc9/10366802/c870ff6fa79b/cmh-2022-0428f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc9/10366802/f983a874da6a/cmh-2022-0428f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc9/10366802/9149859cd8a4/cmh-2022-0428f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc9/10366802/c870ff6fa79b/cmh-2022-0428f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc9/10366802/f983a874da6a/cmh-2022-0428f3.jpg

相似文献

1
A decade of liver organoids: Advances in disease modeling.肝类器官研究的十年进展:疾病建模的新突破
Clin Mol Hepatol. 2023 Jul;29(3):643-669. doi: 10.3350/cmh.2022.0428. Epub 2023 Mar 6.
2
Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids.扩增型人多能干细胞来源的肝样类器官的生成。
J Hepatol. 2019 Nov;71(5):970-985. doi: 10.1016/j.jhep.2019.06.030. Epub 2019 Jul 9.
3
Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease.人多能干细胞衍生类器官作为肝脏疾病模型。
Gastroenterology. 2020 Oct;159(4):1471-1486.e12. doi: 10.1053/j.gastro.2020.06.010. Epub 2020 Jun 15.
4
Organoids of liver diseases: From bench to bedside.肝脏疾病类器官:从基础研究到临床应用。
World J Gastroenterol. 2019 Apr 28;25(16):1913-1927. doi: 10.3748/wjg.v25.i16.1913.
5
Challenges for the Applications of Human Pluripotent Stem Cell-Derived Liver Organoids.人多能干细胞衍生肝类器官应用面临的挑战。
Front Cell Dev Biol. 2021 Oct 1;9:748576. doi: 10.3389/fcell.2021.748576. eCollection 2021.
6
Advances in development and application of human organoids.人类类器官的开发与应用进展
3 Biotech. 2021 Jun;11(6):257. doi: 10.1007/s13205-021-02815-7. Epub 2021 May 8.
7
Stem cells, organoids and their applications for human diseases: Special issue of BMB Reports in 2023.干细胞、类器官及其在人类疾病中的应用:2023 年 BMB 报告特刊
BMB Rep. 2023 Jan;56(1):1. doi: 10.5483/BMBRep.2022-0210.
8
Hepatitis B virus infection modeling using multi-cellular organoids derived from human induced pluripotent stem cells.利用源自人类诱导多能干细胞的多细胞类器官进行乙型肝炎病毒感染建模。
World J Gastroenterol. 2021 Aug 7;27(29):4784-4801. doi: 10.3748/wjg.v27.i29.4784.
9
Bioengineering tissue morphogenesis and function in human neural organoids.在人类神经类器官中生物工程组织形态发生和功能。
Semin Cell Dev Biol. 2021 Mar;111:52-59. doi: 10.1016/j.semcdb.2020.05.025. Epub 2020 Jun 12.
10
Disease Modeling Using 3D Organoids Derived from Human Induced Pluripotent Stem Cells.利用源自人类诱导多能干细胞的 3D 类器官进行疾病建模。
Int J Mol Sci. 2018 Mar 21;19(4):936. doi: 10.3390/ijms19040936.

引用本文的文献

1
"Armed retina"-generating microglial retinal organoids, where are we now?生成“武装视网膜”的小胶质细胞视网膜类器官,我们目前进展如何?
Front Cell Dev Biol. 2025 May 30;13:1574283. doi: 10.3389/fcell.2025.1574283. eCollection 2025.
2
Modeling hepatic steatosis with human adult stem cell-derived liver organoids.利用人成体干细胞来源的肝类器官模拟肝脂肪变性
iScience. 2025 Apr 3;28(5):112344. doi: 10.1016/j.isci.2025.112344. eCollection 2025 May 16.
3
Computational and experimental advances in liver-on-a-chip technology for cancer research: a systematic review.

本文引用的文献

1
Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update.B淋巴细胞在非酒精性脂肪性肝病发病机制中的作用:2022年最新进展
Int J Mol Sci. 2022 Oct 16;23(20):12376. doi: 10.3390/ijms232012376.
2
En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH.大规模类器官表型分析揭示代谢相关遗传易感性与 NASH 的关系。
Cell. 2022 Oct 27;185(22):4216-4232.e16. doi: 10.1016/j.cell.2022.09.031. Epub 2022 Oct 13.
3
Advancements in MAFLD Modeling with Human Cell and Organoid Models.基于人源细胞和类器官模型的 MAFLD 建模进展。
用于癌症研究的芯片上肝脏技术的计算与实验进展:一项系统综述
Biophys Rev. 2024 Dec 14;17(1):151-167. doi: 10.1007/s12551-024-01260-z. eCollection 2025 Feb.
4
Farnesoid X receptor: a potential key target for maintaining liver organoid growth.法尼酯X受体:维持肝类器官生长的潜在关键靶点。
Biomater Transl. 2024 Nov 15;5(4):454-456. doi: 10.12336/biomatertransl.2024.04.011. eCollection 2024.
5
Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects.用于临床前药物安全性评估的先进体外模型:最新进展与展望
Curr Issues Mol Biol. 2024 Dec 26;47(1):7. doi: 10.3390/cimb47010007.
6
Liver organoids: Current advances and future applications for hepatology.肝脏类器官:肝脏学的当前进展与未来应用
Clin Mol Hepatol. 2025 Feb;31(Suppl):S327-S348. doi: 10.3350/cmh.2024.1040. Epub 2024 Dec 26.
7
Ex Vivo Tools and Models in MASLD Research.MASLD 研究中的离体工具和模型。
Cells. 2024 Nov 5;13(22):1827. doi: 10.3390/cells13221827.
8
Generation of -like multicellular liver organoids by mimicking developmental processes: A review.通过模拟发育过程生成类多细胞肝脏类器官:综述
Regen Ther. 2024 Jun 8;26:219-234. doi: 10.1016/j.reth.2024.05.020. eCollection 2024 Jun.
9
Generation and characterization of mature hepatocyte organoids for liver metabolic studies.用于肝脏代谢研究的成熟肝细胞类器官的生成和特征描述。
J Cell Sci. 2024 May 15;137(10). doi: 10.1242/jcs.261961. Epub 2024 May 28.
Int J Mol Sci. 2022 Oct 6;23(19):11850. doi: 10.3390/ijms231911850.
4
SARS-CoV-2 infection of human pluripotent stem cell-derived liver organoids reveals potential mechanisms of liver pathology.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染人多能干细胞衍生的肝类器官揭示了肝脏病理的潜在机制。
iScience. 2022 Oct 21;25(10):105146. doi: 10.1016/j.isci.2022.105146. Epub 2022 Sep 16.
5
Bulevirtide for patients with compensated chronic hepatitis delta: A review.用于代偿期慢性丁型肝炎患者的布立伐昔:综述
Liver Int. 2023 Aug;43 Suppl 1:80-86. doi: 10.1111/liv.15389. Epub 2022 Aug 23.
6
Epidemiological Characteristics of Primary Liver Cancer in Mainland China From 2003 to 2020: A Representative Multicenter Study.2003年至2020年中国大陆原发性肝癌的流行病学特征:一项代表性多中心研究
Front Oncol. 2022 Jun 21;12:906778. doi: 10.3389/fonc.2022.906778. eCollection 2022.
7
Mechanisms of ductular reaction in non-alcoholic steatohepatitis.非酒精性脂肪性肝炎中胆小管反应的机制。
World J Gastroenterol. 2022 May 21;28(19):2088-2099. doi: 10.3748/wjg.v28.i19.2088.
8
Breakthroughs in hepatitis C research: from discovery to cure.丙型肝炎研究的突破:从发现到治愈。
Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):533-550. doi: 10.1038/s41575-022-00608-8. Epub 2022 May 20.
9
EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.表皮生长因子受体抑制可逆转肝癌细胞对仑伐替尼的耐药性。
Sci Rep. 2022 May 14;12(1):8007. doi: 10.1038/s41598-022-12076-w.
10
Mechanistic insight of SARS-CoV-2 infection using human hepatobiliary organoids.利用人肝胆类器官对新型冠状病毒感染的机制性洞察
Gut. 2023 Jan;72(1):216-218. doi: 10.1136/gutjnl-2021-326617. Epub 2022 Apr 22.